Phase Ia study of AVL 292 in volunteers

Trial Profile

Phase Ia study of AVL 292 in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2012

At a glance

  • Drugs Spebrutinib (Primary)
  • Indications Autoimmune disorders; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
    • 24 Jun 2011 Results presented at the Federation of Clinical Immunology Societies (FOCIS) in June 2011.
    • 11 Jun 2011 Results presented at the 16th Congress of the European Haematology Association (EHA-2011).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top